Contributed to PharmaLeaders by Authors: By Ana Bargo, M.S.; Jeannine Cain, MSHI, RHIA, CPHI; Shannon Fee, B.A.; Mark Yap, FNP-C In 2016, a major transformation occurred in how we evaluate clinical data for real-world effectiveness. The FDA signed into law the 21st Century Cures Act, which impacted the Real-World Evidence Program in the U.S. It signaled a paradigm shift in … [Read more...]
Going Virtual
Contributing Author: Chris Mycek, President at WORLEY Pivoting to virtual….Google it, you’ll find it’s a common current theme that will have enduring repercussions on how things get done. Zoom is a new household word, and now a verb as well. Amazon Prime, Netflix, FedEx, are all booming. Nesting at home, with new entertainment centers, pools, and other home luxuries are also … [Read more...]
COVID-19 Accelerates Digital Transformation in Life Sciences
Author: Andy Fuchs, VP of Commercial Strategy, Veeva Systems Public safety is the world’s singular goal as mandatory quarantines, shelter-in-place orders, travel restrictions, and mandatory work-from-home policies go into effect to curb the spread of COVID-19. In response, many biopharmaceutical companies are shifting how they work: Amarin withdrew part of its field force, … [Read more...]
Veeva Introduces Payment Solution for Clin Research Sponsors/CROs and Sites
The success of clinical trials depends on an adequate supply of experienced clinical site investigators. However, the pool of qualified investigators has been shrinking in recent years and a growing proportion of “one-and-done” investigators stop leading clinical trials after one trial. Nearly one-third (30%) of all sites engaged in research currently are first timers. The loss … [Read more...]
Optimizing the Precision Blending of Pharmaceutical Tablets
Contributed by: Leslie Taylor, Power PR. 310-787-1940 ext 419. [email protected] Tumble blender technology enhances the speed and homogeneous blending of tablets and capsules with trace levels of additives To meet stringent regulatory requirements, such as the United States Pharmacopeia (USP), National Formulary (NF) or FDA, as well as production and budgetary demands, … [Read more...]